We previously showed in experimental models that inhibition of FABP4 by a small molecule might be a novel therapeutic strategy against insulin resistance, type 2 diabetes mellitus and atherosclerosis6. This evidence concerns the gene FABP4 and type 2 diabetes mellitus.